ImmuPharma PLC is a drug development business with a pipeline that includes peptide-based treatments in the areas of autoimmunity & inflammation, including Lupuzor, which treats the life threatening disease Lupus.
The stock price has risen by +334.0% in the last month including a single daily gain of 94.0%. The rally came about after ImmuPharma announced positive pre clinical trial results for its P140 autoimmune treatment.
But such has been the reaction in the share price, that the company was forced to make a statement to the effect that it knew of no other news that should affect the share price. Biotech & pharmaceutical research stocks can be notoriously volatile as share prices swing on sentiment, until successful treatments/drug discoveries come to fruition. As such investors should exercise a degree of caution.
To buy shares in ImmuPharma (LON:SCG), you need a share trading platform or share dealing account. Follow these three steps if you want to buy shares in ImmuPharma:
- Decide if you want to buy ImmuPharma shares in the short-term or invest in the long-term
- Compare share dealing and trading fees in our comparison tables
- Choose which broker is right for you and open an account
How much does it cost to buy ImmuPharma shares (LON:IMM)?
Buying one LON:IMM share costs 2.63p. However, as well as the 2.63p cost of buying the shares you will also have to pay stamp duty, dealing and custody account fees for holding your shares with a broker. You also have to consider the difference between the bid price (the price at which you sell shares) and the offer price (the price at which you buy shares). These fees vary depending on what sort of account you open, and with what broker. You can compare the different costs associated with the different types of trading and investing accounts in our comparison tables below.
Best stockbrokers for buying ImmuPharma shares
| Share Dealing Platform | Share Dealing Account Fee | Share Dealing Commission | GIA | ISA | SIPP | LISA | Customer Reviews | More Info |
|---|---|---|---|---|---|---|---|---|
 | £24 - £0 Quarterly | £0 | ✔️ | ✔️ | ✔️ | ❌ | (Based on 678 reviews) | Visit Platform Capital at risk |
 | £4.99 Monthly | £3.99 | ✔️ | ✔️ | ✔️ | ❌ | (Based on 1,119 reviews) | Visit Platform Capital at risk |
 | £0 | £3 | ✔️ | ✔️ | ✔️ | ❌ | (Based on 934 reviews) | Visit Platform Capital at risk |
 | 0.25% - 0% | £5 – £3.50 | ✔️ | ✔️ | ✔️ | ✔️ | (Based on 1,094 reviews) | Visit Platform Capital at risk |
 | 0.45% - 0% | £11.95 – £5.95 | ✔️ | ✔️ | ✔️ | ✔️ | (Based on 1,758 reviews) | Visit Platform Capital at risk |
 | 0.4% – 0.08% | £1 – 0.08% | ✔️ | ✔️ | ✔️ | ❌ | (Based on 73 reviews) | Visit Platform Capital at risk |
Richard is the founder of the Good Money Guide (formerly Good Broker Guide), one of the original investment comparison sites established in 2015. With a career spanning two decades as a broker, he brings extensive expertise and knowledge to the financial landscape.
Having worked as a broker at Investors Intelligence and a multi-asset derivatives broker at MF Global (Man Financial), Richard has acquired substantial experience in the industry. His career began as a private client stockbroker at Walker Crips and Phillip Securities (now King and Shaxson), following internships on the NYMEX oil trading floor in New York and London IPE in 2001 and 2000.
Richard’s contributions and expertise have been recognized by respected publications such as The Sunday Times, BusinessInsider, Yahoo Finance, BusinessNews.org.uk, Master Investor, Wealth Briefing, iNews, and The FT, among many others.
Under Richard’s leadership, the Good Money Guide has evolved into a valuable destination for comprehensive information and expert guidance, specialising in trading, investment, and currency exchange. His commitment to delivering high-quality insights has solidified the Good Money Guide’s standing as a well-respected resource for both customers and industry colleagues.
You can contact Richard at richard@goodmoneyguide.com
